Reprogramming miRNAs global expression orchestrates development of drug resistance in BRAF mutated melanoma

Luigi Fattore, Ciro Francesco Ruggiero, Maria Elena Pisanu, Domenico Liguoro, Andrea Cerri, Susan Costantini, Francesca Capone, Mario Acunzo, Giulia Romano, Giovanni Nigita, Domenico Mallardo, Concetta Ragone, Maria Vincenza Carriero, Alfredo Budillon, Gerardo Botti, Paolo Antonio Ascierto, Rita Mancini, Gennaro Ciliberto

Research output: Contribution to journalArticle

Abstract

Drug resistance imposes severe limitations to the efficacy of targeted therapy in BRAF-mutated metastatic melanoma. Although this issue has been mitigated by the development of combination therapies with BRAF plus MEK inhibitors, drug resistance inevitably occurs with time and results in clinical recurrences and untreatable disease. Hence, there is strong need of developing new combination therapies and non-invasive diagnostics for the early identification of drug-resistant patients. We report here that the development of drug resistance to BRAFi is dominated by a dynamic deregulation of a large population of miRNAs, leading to the alteration of cell intrinsic proliferation and survival pathways, as well as of proinflammatory and proangiogenic cues, where a prominent role is played by the miR-199b-5p/VEGF axis. Significant alterations of miRNA expression levels are detectable in tumor biopsies and plasma from patients after disease recurrence. Targeting these alterations blunts the development of drug resistance.

Original languageEnglish
Pages (from-to)1267-1282
Number of pages16
JournalCell Death and Differentiation
Volume26
Issue number7
DOIs
Publication statusPublished - Jul 2019

Fingerprint

MicroRNAs
Drug Resistance
Melanoma
Recurrence
Mitogen-Activated Protein Kinase Kinases
Vascular Endothelial Growth Factor A
Cues
Cell Survival
Therapeutics
Cell Proliferation
Biopsy
Pharmaceutical Preparations
Population
Neoplasms

Cite this

Reprogramming miRNAs global expression orchestrates development of drug resistance in BRAF mutated melanoma. / Fattore, Luigi; Ruggiero, Ciro Francesco; Pisanu, Maria Elena; Liguoro, Domenico; Cerri, Andrea; Costantini, Susan; Capone, Francesca; Acunzo, Mario; Romano, Giulia; Nigita, Giovanni; Mallardo, Domenico; Ragone, Concetta; Carriero, Maria Vincenza; Budillon, Alfredo; Botti, Gerardo; Ascierto, Paolo Antonio; Mancini, Rita; Ciliberto, Gennaro.

In: Cell Death and Differentiation, Vol. 26, No. 7, 07.2019, p. 1267-1282.

Research output: Contribution to journalArticle

Fattore, L, Ruggiero, CF, Pisanu, ME, Liguoro, D, Cerri, A, Costantini, S, Capone, F, Acunzo, M, Romano, G, Nigita, G, Mallardo, D, Ragone, C, Carriero, MV, Budillon, A, Botti, G, Ascierto, PA, Mancini, R & Ciliberto, G 2019, 'Reprogramming miRNAs global expression orchestrates development of drug resistance in BRAF mutated melanoma', Cell Death and Differentiation, vol. 26, no. 7, pp. 1267-1282. https://doi.org/10.1038/s41418-018-0205-5
Fattore, Luigi ; Ruggiero, Ciro Francesco ; Pisanu, Maria Elena ; Liguoro, Domenico ; Cerri, Andrea ; Costantini, Susan ; Capone, Francesca ; Acunzo, Mario ; Romano, Giulia ; Nigita, Giovanni ; Mallardo, Domenico ; Ragone, Concetta ; Carriero, Maria Vincenza ; Budillon, Alfredo ; Botti, Gerardo ; Ascierto, Paolo Antonio ; Mancini, Rita ; Ciliberto, Gennaro. / Reprogramming miRNAs global expression orchestrates development of drug resistance in BRAF mutated melanoma. In: Cell Death and Differentiation. 2019 ; Vol. 26, No. 7. pp. 1267-1282.
@article{1087b1f1136b494f87c90079d22076ff,
title = "Reprogramming miRNAs global expression orchestrates development of drug resistance in BRAF mutated melanoma",
abstract = "Drug resistance imposes severe limitations to the efficacy of targeted therapy in BRAF-mutated metastatic melanoma. Although this issue has been mitigated by the development of combination therapies with BRAF plus MEK inhibitors, drug resistance inevitably occurs with time and results in clinical recurrences and untreatable disease. Hence, there is strong need of developing new combination therapies and non-invasive diagnostics for the early identification of drug-resistant patients. We report here that the development of drug resistance to BRAFi is dominated by a dynamic deregulation of a large population of miRNAs, leading to the alteration of cell intrinsic proliferation and survival pathways, as well as of proinflammatory and proangiogenic cues, where a prominent role is played by the miR-199b-5p/VEGF axis. Significant alterations of miRNA expression levels are detectable in tumor biopsies and plasma from patients after disease recurrence. Targeting these alterations blunts the development of drug resistance.",
author = "Luigi Fattore and Ruggiero, {Ciro Francesco} and Pisanu, {Maria Elena} and Domenico Liguoro and Andrea Cerri and Susan Costantini and Francesca Capone and Mario Acunzo and Giulia Romano and Giovanni Nigita and Domenico Mallardo and Concetta Ragone and Carriero, {Maria Vincenza} and Alfredo Budillon and Gerardo Botti and Ascierto, {Paolo Antonio} and Rita Mancini and Gennaro Ciliberto",
year = "2019",
month = "7",
doi = "10.1038/s41418-018-0205-5",
language = "English",
volume = "26",
pages = "1267--1282",
journal = "Cell Death and Differentiation",
issn = "1350-9047",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Reprogramming miRNAs global expression orchestrates development of drug resistance in BRAF mutated melanoma

AU - Fattore, Luigi

AU - Ruggiero, Ciro Francesco

AU - Pisanu, Maria Elena

AU - Liguoro, Domenico

AU - Cerri, Andrea

AU - Costantini, Susan

AU - Capone, Francesca

AU - Acunzo, Mario

AU - Romano, Giulia

AU - Nigita, Giovanni

AU - Mallardo, Domenico

AU - Ragone, Concetta

AU - Carriero, Maria Vincenza

AU - Budillon, Alfredo

AU - Botti, Gerardo

AU - Ascierto, Paolo Antonio

AU - Mancini, Rita

AU - Ciliberto, Gennaro

PY - 2019/7

Y1 - 2019/7

N2 - Drug resistance imposes severe limitations to the efficacy of targeted therapy in BRAF-mutated metastatic melanoma. Although this issue has been mitigated by the development of combination therapies with BRAF plus MEK inhibitors, drug resistance inevitably occurs with time and results in clinical recurrences and untreatable disease. Hence, there is strong need of developing new combination therapies and non-invasive diagnostics for the early identification of drug-resistant patients. We report here that the development of drug resistance to BRAFi is dominated by a dynamic deregulation of a large population of miRNAs, leading to the alteration of cell intrinsic proliferation and survival pathways, as well as of proinflammatory and proangiogenic cues, where a prominent role is played by the miR-199b-5p/VEGF axis. Significant alterations of miRNA expression levels are detectable in tumor biopsies and plasma from patients after disease recurrence. Targeting these alterations blunts the development of drug resistance.

AB - Drug resistance imposes severe limitations to the efficacy of targeted therapy in BRAF-mutated metastatic melanoma. Although this issue has been mitigated by the development of combination therapies with BRAF plus MEK inhibitors, drug resistance inevitably occurs with time and results in clinical recurrences and untreatable disease. Hence, there is strong need of developing new combination therapies and non-invasive diagnostics for the early identification of drug-resistant patients. We report here that the development of drug resistance to BRAFi is dominated by a dynamic deregulation of a large population of miRNAs, leading to the alteration of cell intrinsic proliferation and survival pathways, as well as of proinflammatory and proangiogenic cues, where a prominent role is played by the miR-199b-5p/VEGF axis. Significant alterations of miRNA expression levels are detectable in tumor biopsies and plasma from patients after disease recurrence. Targeting these alterations blunts the development of drug resistance.

U2 - 10.1038/s41418-018-0205-5

DO - 10.1038/s41418-018-0205-5

M3 - Article

C2 - 30254376

VL - 26

SP - 1267

EP - 1282

JO - Cell Death and Differentiation

JF - Cell Death and Differentiation

SN - 1350-9047

IS - 7

ER -